Literature DB >> 31308666

Lipid-polymer hybrid nanoparticles for controlled delivery of hydrophilic and lipophilic doxorubicin for breast cancer therapy.

Nayab Tahir1,2,3, Asadullah Madni2, Alexandra Correia3, Mubashar Rehman4, Vimalkumar Balasubramanian3, Muhammad Muzamil Khan2, Hélder A Santos3,5.   

Abstract

Background: Lipid polymer hybrid nanoparticles (LPHNPs) for the controlled delivery of hydrophilic doxorubicin hydrochloride (DOX.HCl) and lipophilic DOX base have been fabricated by the single step modified nanoprecipitation method. Materials and methods: Poly (D, L-lactide-co-glicolide) (PLGA), lecithin, and 1,2-distearoyl-Sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000 (DSPE-PEG 2000) were selected as structural components.
Results: The mean particle size was 173-208 nm, with an encapsulation efficiency of 17.8±1.9 to 43.8±4.4% and 40.3±0.6 to 59. 8±1.4% for DOX.HCl and DOX base, respectively. The drug release profile was in the range 33-57% in 24 hours and followed the Higuchi model (R2=0.9867-0.9450) and Fickian diffusion (n<0.5). However, the release of DOX base was slower than DOX.HCl. The in vitro cytotoxicity studies and confocal imaging showed safety, good biocompatibility, and a higher degree of particle internalization. The higher internalization of DOX base was attributed to higher permeability of lipophilic component and better hydrophobic interaction of particles with cell membranes. Compared to the free DOX, the DOX.HCl and DOX base loaded LPHNPs showed higher antiproliferation effects in MDA-MB231 and PC3 cells.
Conclusion: Therefore, LPHNPs have provided a potential drug delivery strategy for safe, controlled delivery of both hydrophilic and lipophilic form of DOX in cancer cells.

Entities:  

Keywords:  breast cancer; doxorubicin; drug delivery; lipid polymer hybrid; nanotechnology

Mesh:

Substances:

Year:  2019        PMID: 31308666      PMCID: PMC6617603          DOI: 10.2147/IJN.S209325

Source DB:  PubMed          Journal:  Int J Nanomedicine        ISSN: 1176-9114


  51 in total

Review 1.  Anthracyclines: selected new developments.

Authors:  M Binaschi; M Bigioni; A Cipollone; C Rossi; C Goso; C A Maggi; G Capranico; F Animati
Journal:  Curr Med Chem Anticancer Agents       Date:  2001-08

2.  PLA/PLGA nanoparticles for sustained release of docetaxel.

Authors:  T Musumeci; C A Ventura; I Giannone; B Ruozi; L Montenegro; R Pignatello; G Puglisi
Journal:  Int J Pharm       Date:  2006-06-23       Impact factor: 5.875

Review 3.  Anthracyclines in the treatment of gynecologic malignancies.

Authors:  F C Maluf; D Spriggs
Journal:  Gynecol Oncol       Date:  2002-04       Impact factor: 5.482

4.  In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.

Authors:  Ho Lun Wong; Andrew Mike Rauth; Reina Bendayan; Xiao Yu Wu
Journal:  Eur J Pharm Biopharm       Date:  2006-11-07       Impact factor: 5.571

5.  Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats.

Authors:  D R Kalaria; G Sharma; V Beniwal; M N V Ravi Kumar
Journal:  Pharm Res       Date:  2008-11-08       Impact factor: 4.200

6.  Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin.

Authors:  Robhash Kusam Subedi; Keon Wook Kang; Hoo-Kyun Choi
Journal:  Eur J Pharm Sci       Date:  2009-05-03       Impact factor: 4.384

7.  Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery.

Authors:  Qingzhi Lv; Aihua Yu; Yanwei Xi; Houli Li; Zhimei Song; Jing Cui; Fengliang Cao; Guangxi Zhai
Journal:  Int J Pharm       Date:  2009-01-22       Impact factor: 5.875

8.  A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS.

Authors:  L Mu; S S Feng
Journal:  J Control Release       Date:  2003-01-09       Impact factor: 9.776

9.  Molecular interactions, internal structure and drug release kinetics of rationally developed polymer-lipid hybrid nanoparticles.

Authors:  Yongqiang Li; Ho Lun Wong; Adam J Shuhendler; Andrew M Rauth; Xiao Yu Wu
Journal:  J Control Release       Date:  2008-03-05       Impact factor: 9.776

10.  Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups.

Authors:  Carolina Salvador-Morales; Liangfang Zhang; Robert Langer; Omid C Farokhzad
Journal:  Biomaterials       Date:  2009-01-23       Impact factor: 12.479

View more
  16 in total

Review 1.  Characteristics of Graphene Oxide for Gene Transfection and Controlled Release in Breast Cancer Cells.

Authors:  Francesca Grilli; Parisa Hajimohammadi Gohari; Shan Zou
Journal:  Int J Mol Sci       Date:  2022-06-18       Impact factor: 6.208

2.  Functional Albumin Nanoformulations to Fight Adrenocortical Carcinoma: a Redox-Responsive Approach.

Authors:  Manuela Curcio; Paola Avena; Giuseppe Cirillo; Ivan Casaburi; Umile Gianfranco Spizzirri; Fiore Pasquale Nicoletta; Francesca Iemma; Vincenzo Pezzi
Journal:  Pharm Res       Date:  2020-02-14       Impact factor: 4.200

3.  Assessment of the hepatoprotective effect of developed lipid-polymer hybrid nanoparticles (LPHNPs) encapsulating naturally extracted β-Sitosterol against CCl4 induced hepatotoxicity in rats.

Authors:  Ebtsam M Abdou; Marwa A A Fayed; Doaa Helal; Kawkab A Ahmed
Journal:  Sci Rep       Date:  2019-12-24       Impact factor: 4.379

4.  Interaction of Immune Cells and Tumor Cells in Gold Nanorod-Gelatin Composite Porous Scaffolds.

Authors:  Xiuhui Wang; Naoki Kawazoe; Guoping Chen
Journal:  Nanomaterials (Basel)       Date:  2019-09-24       Impact factor: 5.076

5.  Development of Drug Dual-Carriers Delivery System with Mitochondria-Targeted and pH/Heat Responsive Capacity for Synergistic Photothermal-Chemotherapy of Ovarian Cancer.

Authors:  Xiaoxia Guo; Jie Mei; Chunping Zhang
Journal:  Int J Nanomedicine       Date:  2020-01-16

6.  Mini-Tablets versus Nanoparticles for Controlling the Release of Amoxicillin: In vitro/In vivo Study.

Authors:  Dalia A Gaber; Hessah S Alhawas; Fatimah A Alfadhel; Siham A Abdoun; Amal M Alsubaiyel; Rehab M Alsawi
Journal:  Drug Des Devel Ther       Date:  2020-12-07       Impact factor: 4.162

7.  Chemopreventive Effect of 5-Flurouracil Polymeric Hybrid PLGA-Lecithin Nanoparticles against Colon Dysplasia Model in Mice and Impact on p53 Apoptosis.

Authors:  Mohammed A Attia; Eman T Enan; Abdullah A Hashish; Sherif M H El-Kannishy; Ahmed R Gardouh; Mona K Tawfik; Salwa Faisal; Amr El-Mistekawy; Ayman Salama; Suliman Y Alomar; Amira H Eltrawy; Sheka Yagub Aloyouni; Sawsan A Zaitone
Journal:  Biomolecules       Date:  2021-01-15

Review 8.  Engineering of small-molecule lipidic prodrugs as novel nanomedicines for enhanced drug delivery.

Authors:  Lingling Huang; Jianmiao Yang; Tiantian Wang; Jianqing Gao; Donghang Xu
Journal:  J Nanobiotechnology       Date:  2022-01-24       Impact factor: 10.435

9.  Diacerein-Loaded Hyaluosomes as a Dual-Function Platform for Osteoarthritis Management via Intra-Articular Injection: In Vitro Characterization and In Vivo Assessment in a Rat Model.

Authors:  Nouran O Eladawy; Nadia M Morsi; Rehab N Shamma
Journal:  Pharmaceutics       Date:  2021-05-21       Impact factor: 6.321

Review 10.  Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy.

Authors:  Ayeskanta Mohanty; Saji Uthaman; In-Kyu Park
Journal:  Molecules       Date:  2020-09-23       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.